8-K/A: McKesson Reports Strong Q3 Results, Raises Full-Year Adjusted EPS Guidance

McKesson Corporation announced an 18% increase in consolidated revenues for the third quarter of fiscal year 2025 and raised its full-year adjusted earnings per diluted share guidance.

Summary

• McKesson Corporation reported its third quarter fiscal year 2025 results, showing strong revenue and profit growth.
• Consolidated revenues increased by 18% to $95.3 billion.
• Earnings per diluted share increased by $2.53 to $6.95.
• Adjusted earnings per diluted share increased by 4% to $8.03.
• The company raised and narrowed its full-year adjusted earnings per diluted share guidance to a range of $32.55 to $32.95, indicating a 19% to 20% growth compared to the prior year.
• McKesson signed a definitive agreement to acquire a controlling interest in PRISM Vision Holdings, LLC.
• McKesson closed the transaction to sell its Canada-based Rexall and Well.ca retail businesses on December 30, 2024.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial results, increased guidance, and strategic acquisitions, indicating a favorable sentiment.

Positives

• Strong revenue growth of 18% driven by the U.S. Pharmaceutical segment, including increased prescription volumes and growth in the oncology platform.
• Adjusted Operating Profit growth of 16%.
• Increased prescription volumes in the third-party logistics and technology services businesses.
• Operational efficiencies from cost optimization initiatives in the Medical-Surgical Solutions segment.
• Higher pharmaceutical distribution volumes in the Canadian business.
• The company returned $3.1 billion of cash to shareholders in the first nine months of the fiscal year.
• McKesson Ventures' equity investments contributed pre-tax gains of $6 million.

Negatives

• Net income attributable to McKesson Corporation decreased by 8% for the first nine months of the fiscal year.
• Medical-Surgical Solutions segment revenues decreased by 3%, driven by lower contributions from illness season vaccines and testing in the primary care channel.
• The company used cash from operations of $1.7 billion and invested $581 million in capital expenditures, resulting in negative Free Cash Flow of $2.2 billion for the first nine months of the fiscal year.

Risks

• The company acknowledges various risk factors that could cause actual results to differ materially from forward-looking statements, including legal disputes, regulatory changes, cybersecurity incidents, and economic changes.
• The company is subject to frequently changing, extensive, complex, and challenging healthcare and other laws.
• The company might be adversely impacted by regulatory delays or other difficulties with acquisitions or divestitures.
• The company might be adversely impacted by healthcare reform such as changes in pricing and reimbursement models.
• The company might be adversely impacted by changes in the economic environments in which it operates.

Future Outlook

McKesson is raising and narrowing its fiscal 2025 Adjusted Earnings per Diluted Share guidance to $32.55 to $32.95.

Management Comments

• Brian Tyler, chief executive officer, stated that McKesson reported strong third quarter operational results with broad-based Revenue growth of 18% and Adjusted Operating Profit growth of 16%.
• Mr. Tyler added that the company remains committed to its enterprise growth strategy, including its growth pillars within oncology and biopharma services.
• Mr. Tyler also announced the signing of a definitive agreement to acquire a controlling interest in PRISM Vision Holdings, in support of McKesson's leadership in community practice management and specialty solutions.

Industry Context

The acquisition of PRISM Vision Holdings indicates McKesson's strategic focus on expanding its presence in the high-growth area of retina and ophthalmology, leveraging its expertise in practice management and clinical research outcomes.

Comparison to Industry Standards

• McKesson's revenue growth of 18% in Q3 is strong compared to peers in the pharmaceutical distribution industry.
• AmerisourceBergen and Cardinal Health, two major competitors, have shown similar strategic interests in specialty services and acquisitions to drive growth.
• The adjusted EPS guidance indicates a positive outlook, aligning with industry trends of increasing demand for healthcare services.

Management Changes

Stakeholder Impact

• Shareholders will benefit from increased earnings and the return of capital through share repurchases and dividends.
• The acquisition of PRISM Vision Holdings could lead to improved services for providers, biopharma partners, and patients.
• Employees may experience opportunities for growth and development as the company expands its operations.

Next Steps

• McKesson will continue to execute against its enterprise growth strategy.
• The company will work towards closing the acquisition of PRISM Vision Holdings, LLC.
• McKesson management will participate in the TD Cowen 45th Annual Healthcare Conference on March 4, 2025.

Key Dates

Keywords

McKesson, financial results, earnings, revenue, guidance, pharmaceutical, oncology, PRISM Vision Holdings, acquisition, divestiture